WALTHAM, Mass. & NEW YORK--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today will present an update on the progress of its late-stage and emerging clinical product candidates from the company’s proprietary technology platforms at its Research and Development (R&D) Day for analysts and investors in New York.
